Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Single and Multiple Ascending Dose and Food Effect Study of NEU-411 Administered Orally to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects

NCT05755191 is registered in ClinicalTrials.gov with Neuron23 Inc. as lead sponsor.

Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05755191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Single and Multiple Ascending Dose and Food Effect Study of NEU-411 Administered Orally to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects
Lead sponsor
Neuron23 Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 13, 2023
Completion date
June 3, 2024
Enrollment
147 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy